Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)

Clinical trial NCT00303472 · COMPLETED

Trial details

NCT number: NCT00303472
Sponsor: Amgen
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Thrombocytopenia MDS Myelodysplastic Syndromes Refractory Cytopenias

Start date: 2006-02-01
Primary completion: 2008-05-01
Enrollment: 72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.